Abstract:Abstract: Objective?To investigate the diagnostic and application value of electronic bronchoscope combined with rapid on site evaluation (ROSE) for the diagnosis of different bronchial infiltrative and compressive type lung cancer.?Methods?A retrospective analysis was performed from January 2016 to January 2018 with 265 patients finally diagnosed lung cancer. These lung cancer patients are only bronchial infiltrating and compressive type lung cancer seen under electronic bronchoscope. The patients were divided into two groups, 131 patients were in ROSE group and 134 patients in non-ROSE group. The diagnostic rates and pathological diagnostic costs of these two groups were compared, and the consistency between ROSE and the final pathological results were analyzed.?Results?There was a statistically significant difference in diagnosis rate between ROSE and non-ROSE groups for bronchial infiltrating type cancer (97.1% vs 66.9%, P?0.05) and compressive type cancer (89.3% vs 56.0%, P?0.05). For pathological diagnostic cost, ROSE group was significantly lower than non-ROSE group (t?=?6.02, P?0.05), diagnostic accuracy rate of squamous cell carcinoma, adenocarcinoma and small cell carcinoma was 89.3%, 92.3%, 99.2% respectively.?Conclusions?The combination of electronic bronchoscope with ROSE can improve the diagnostic rate of bronchial infiltrative and compressive type lung cancer, and reduce the pathological diagnostic cost of lung cancer patients. ROSE can make a rapid diagnosis and classification of lung cancer with biopsy specimen on site, especially for small cell lung cancer diagnosis and its accuracy rate with pathological results can reach up to 99.2%. Electronic bronchoscope combined with ROSE has a certain application value in bronchial infiltrative type and compressive type lung cancer.